The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.
about
The functional contrariety of JNKJNK signalling in cancer: in need of new, smarter therapeutic targetsIntegrin-dependent activation of the JNK signaling pathway by mechanical stressSP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinaseRole of JNK in a Trp53-dependent mouse model of breast cancer.MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastomaInhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent mannerDeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistanceOral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasmPotential roles of antisense technology in cancer chemotherapy.Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs.ERK and JNK activation is essential for oncogenic transformation by v-Rel.ROS, stress-activated kinases and stress signaling in cancer.c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8).Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation.Palytoxin: exploiting a novel skin tumor promoter to explore signal transduction and carcinogenesis.Suppression of Ras-stimulated transformation by the JNK signal transduction pathwayRole of JNK activation in apoptosis: a double-edged sword.Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes.Structure, functional regulation and signaling properties of Rap2B.Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategyA microalga, Euglena tuba induces apoptosis and suppresses metastasis in human lung and breast carcinoma cells through ROS-mediated regulation of MAPKsc-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells.Production of human epidermal growth factor using adenoviral based system.Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.Molecular mechanisms underlying the time-dependent autophagy and apoptosis induced by nutrient depletion in multiple myeloma: a pilot study.The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition.Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway.The tumor-growth inhibitory activity of flavanone and 2'-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs.PAK4 functions in tumor necrosis factor (TNF) alpha-induced survival pathways by facilitating TRADD binding to the TNF receptor.DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferationIdentification of a specific domain responsible for JNK2alpha2 autophosphorylation.Inducible expression of a constitutively active mutant of mitogen-activated protein kinase kinase 7 specifically activates c-JUN NH2-terminal protein kinase, alters expression of at least nine genes, and inhibits cell proliferation.Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by IkappaBbeta.Activation of the luteinizing hormone beta promoter by gonadotropin-releasing hormone requires c-Jun NH2-terminal protein kinase.
P2860
Q24633325-E3232403-2286-48DB-826C-A441B5CA5CAFQ27023869-FF903C63-0F46-4345-AD66-922599A643BBQ27316735-F68B2164-D2CC-40C8-A683-0E41EEF43F2EQ28364720-7DF1C367-BC2B-4E4B-B1E7-FD0A665B4D93Q33683349-D3F797AD-A5D0-4C5E-91D6-BBC5C79FE22FQ33803485-F7F270BA-2D32-459D-B3A1-6DF7AAABC5A7Q33962291-476BC228-0ED9-4E7E-ADA4-414FBBDFF6EFQ34067050-2919008C-E85B-40F4-9BCA-29C4067C6BC1Q34103146-B9CA2069-B1B1-4603-B5AE-4EBB13FC4FE7Q34293601-A6E3FAB9-0D8E-4DA8-80B7-DD60DACF7D7FQ34298362-F95C7E48-A417-48D4-9A0D-FE4D409887A3Q34351185-BD7EF0A4-521C-4139-85F6-2A96DF112609Q34625850-E7D4A96A-2D27-4152-9A8D-55BF46446264Q34869169-E28DFA3A-E90B-49D6-8309-3049C91887CBQ35102076-53F5EE8D-09F4-4C04-BB3F-D8682AD8BBDBQ35585553-CCA69BB0-13CD-4452-8754-B7A206FFEBA2Q35964337-56C4565E-9BCF-40B1-9041-83FEACDB257FQ36027363-6F6031AE-FB65-4C1A-85FA-14D8E3F3964AQ36430224-D4BDCEF4-34B7-4B3A-8F92-369DAFEB8773Q36741049-A381FFA9-FDBE-41CD-B7C1-E1C6B989B4F8Q36878711-768DE238-DA0C-4EAC-AF50-21F09D8B43C8Q36949142-595B6352-5C17-4D65-B927-802F6147B9D4Q37054908-8EE5B128-33F4-4D8B-A189-4BDE7CDB3B7BQ37174638-A4093C5B-41FB-4243-BEDE-72DB2B1BEEB8Q37670063-679A1E1E-3C54-4045-B5C5-D4CCF374774EQ37741008-F37403F5-D4BF-44EE-A75A-8D1119C9D16DQ39068847-72E4458A-823E-4B43-8103-BD9BD60217E5Q39226835-0207CB66-9DE9-4D45-BD04-AB8AEF150A98Q39264005-7DE0C447-45BA-4EA2-BFA1-EB767BF02094Q39405477-E930D9D6-D2A7-4413-9A7D-543D57DD7C49Q40021818-6763E4D5-AA50-47CD-B3C9-184CCA10A15AQ40064172-D2A5C05A-5BFB-4936-8030-2D376F7B4B16Q40127941-08148624-131B-461E-B459-1AE17E729F8BQ40221897-B561523A-A8B9-4FC3-BF00-04C63BFE38E5Q40361376-07B397D3-BA61-4AFC-AC12-BD84358BB2ADQ40415661-0C69D831-0E05-419B-AF61-C0A3904DFC9BQ40473949-D32F9EB3-F4C7-4657-85DB-0D7560A72FB0Q40767784-41F7AE10-C156-41E8-9FE6-67048F43DBC7Q40799697-F6CAAA59-2600-4BA1-BC49-296DE40698A0Q40883233-18C86C64-D6ED-41C3-BC4A-C06D0285B502
P2860
The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The Jun kinase 2 isoform is pr ...... man A549 lung carcinoma cells.
@ast
The Jun kinase 2 isoform is pr ...... man A549 lung carcinoma cells.
@en
type
label
The Jun kinase 2 isoform is pr ...... man A549 lung carcinoma cells.
@ast
The Jun kinase 2 isoform is pr ...... man A549 lung carcinoma cells.
@en
prefLabel
The Jun kinase 2 isoform is pr ...... man A549 lung carcinoma cells.
@ast
The Jun kinase 2 isoform is pr ...... man A549 lung carcinoma cells.
@en
P2093
P2860
P356
P1476
The Jun kinase 2 isoform is pr ...... man A549 lung carcinoma cells.
@en
P2093
P2860
P304
P356
10.1128/MCB.19.3.1938
P407
P577
1999-03-01T00:00:00Z